Get Premium to unlock powerful stock data

Ra Capital Management, L.p. Buys Eliem Therapeutics Inc, Adagio Therapeutics Inc, Cytek Biosciences Inc, Sells Axsome Therapeutics Inc, Curis Inc, Cerevel Therapeutics Holdings Inc

Author's Avatar
insider
Nov 16, 2021
Article's Main Image
Investment company Ra Capital Management, L.p. (Current Portfolio) buys Eliem Therapeutics Inc, Adagio Therapeutics Inc, Cytek Biosciences Inc, Icosavax Inc, DICE Therapeutics Inc, sells Axsome Therapeutics Inc, Curis Inc, Cerevel Therapeutics Holdings Inc, Trillium Therapeutics Inc, Ardelyx Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Ra Capital Management, L.p.. As of 2021Q3, Ra Capital Management, L.p. owns 95 stocks with a total value of $7.2 billion. These are the details of the buys and sells.

For the details of RA CAPITAL MANAGEMENT, L.P.'s stock buys and sells, go to https://www.gurufocus.com/guru/ra+capital+management%2C+l.p./current-portfolio/portfolio

These are the top 5 holdings of RA CAPITAL MANAGEMENT, L.P.
  1. Ascendis Pharma A/S (ASND) - 7,387,900 shares, 16.32% of the total portfolio. Shares added by 8.54%
  2. Novavax Inc (NVAX) - 2,097,794 shares, 6.03% of the total portfolio. Shares reduced by 18.05%
  3. Eliem Therapeutics Inc (ELYM) - 13,150,849 shares, 3.28% of the total portfolio. New Position
  4. Adagio Therapeutics Inc (ADGI) - 5,340,130 shares, 3.13% of the total portfolio. New Position
  5. Forma Therapeutics Holdings Inc (FMTX) - 9,011,651 shares, 2.90% of the total portfolio.
New Purchase: Eliem Therapeutics Inc (ELYM)

Ra Capital Management, L.p. initiated holding in Eliem Therapeutics Inc. The purchase prices were between $14.45 and $28.61, with an estimated average price of $20.84. The stock is now traded at around $18.180000. The impact to a portfolio due to this purchase was 3.28%. The holding were 13,150,849 shares as of 2021-09-30.

New Purchase: Adagio Therapeutics Inc (ADGI)

Ra Capital Management, L.p. initiated holding in Adagio Therapeutics Inc. The purchase prices were between $20.88 and $56.08, with an estimated average price of $37.24. The stock is now traded at around $20.200000. The impact to a portfolio due to this purchase was 3.13%. The holding were 5,340,130 shares as of 2021-09-30.

New Purchase: Cytek Biosciences Inc (CTKB)

Ra Capital Management, L.p. initiated holding in Cytek Biosciences Inc. The purchase prices were between $17.52 and $27.93, with an estimated average price of $23.54. The stock is now traded at around $22.950000. The impact to a portfolio due to this purchase was 2.85%. The holding were 9,607,028 shares as of 2021-09-30.

New Purchase: Icosavax Inc (ICVX)

Ra Capital Management, L.p. initiated holding in Icosavax Inc. The purchase prices were between $24.85 and $40.25, with an estimated average price of $34.02. The stock is now traded at around $26.790000. The impact to a portfolio due to this purchase was 2.37%. The holding were 5,779,347 shares as of 2021-09-30.

New Purchase: DICE Therapeutics Inc (DICE)

Ra Capital Management, L.p. initiated holding in DICE Therapeutics Inc. The purchase prices were between $31.92 and $37, with an estimated average price of $34.06. The stock is now traded at around $34.150000. The impact to a portfolio due to this purchase was 2.36%. The holding were 5,208,911 shares as of 2021-09-30.

New Purchase: Acumen Pharmaceuticals Inc (ABOS)

Ra Capital Management, L.p. initiated holding in Acumen Pharmaceuticals Inc. The purchase prices were between $14.5 and $20.28, with an estimated average price of $16.68. The stock is now traded at around $10.730000. The impact to a portfolio due to this purchase was 2.01%. The holding were 9,770,773 shares as of 2021-09-30.

Added: Centessa Pharmaceuticals PLC (CNTA)

Ra Capital Management, L.p. added to a holding in Centessa Pharmaceuticals PLC by 179.39%. The purchase prices were between $16.7 and $23.11, with an estimated average price of $20.76. The stock is now traded at around $12.540000. The impact to a portfolio due to this purchase was 0.53%. The holding were 3,577,094 shares as of 2021-09-30.

Added: TG Therapeutics Inc (TGTX)

Ra Capital Management, L.p. added to a holding in TG Therapeutics Inc by 22.60%. The purchase prices were between $21.78 and $40.45, with an estimated average price of $31.07. The stock is now traded at around $26.640000. The impact to a portfolio due to this purchase was 0.35%. The holding were 4,098,332 shares as of 2021-09-30.

Added: EyePoint Pharmaceuticals Inc (EYPT)

Ra Capital Management, L.p. added to a holding in EyePoint Pharmaceuticals Inc by 76.84%. The purchase prices were between $7.51 and $11.72, with an estimated average price of $9.55. The stock is now traded at around $14.050000. The impact to a portfolio due to this purchase was 0.14%. The holding were 2,210,506 shares as of 2021-09-30.

Added: Astria Therapeutics Inc (ATXS)

Ra Capital Management, L.p. added to a holding in Astria Therapeutics Inc by 27.33%. The purchase prices were between $7.32 and $12.9, with an estimated average price of $9.62. The stock is now traded at around $6.920000. The impact to a portfolio due to this purchase was 0.03%. The holding were 1,262,193 shares as of 2021-09-30.

Sold Out: Axsome Therapeutics Inc (AXSM)

Ra Capital Management, L.p. sold out a holding in Axsome Therapeutics Inc. The sale prices were between $19.91 and $68.26, with an estimated average price of $39.19.

Sold Out: Curis Inc (CRIS)

Ra Capital Management, L.p. sold out a holding in Curis Inc. The sale prices were between $6.94 and $8.85, with an estimated average price of $7.82.

Sold Out: Cerevel Therapeutics Holdings Inc (CERE)

Ra Capital Management, L.p. sold out a holding in Cerevel Therapeutics Holdings Inc. The sale prices were between $21.26 and $38.85, with an estimated average price of $28.11.

Sold Out: Trillium Therapeutics Inc (TRIL)

Ra Capital Management, L.p. sold out a holding in Trillium Therapeutics Inc. The sale prices were between $5.86 and $17.8, with an estimated average price of $11.74.

Sold Out: Ardelyx Inc (ARDX)

Ra Capital Management, L.p. sold out a holding in Ardelyx Inc. The sale prices were between $1.27 and $8.17, with an estimated average price of $2.73.

Sold Out: Legend Biotech Corp (LEGN)

Ra Capital Management, L.p. sold out a holding in Legend Biotech Corp. The sale prices were between $35.31 and $50.56, with an estimated average price of $41.56.



Here is the complete portfolio of RA CAPITAL MANAGEMENT, L.P.. Also check out:

1. RA CAPITAL MANAGEMENT, L.P.'s Undervalued Stocks
2. RA CAPITAL MANAGEMENT, L.P.'s Top Growth Companies, and
3. RA CAPITAL MANAGEMENT, L.P.'s High Yield stocks
4. Stocks that RA CAPITAL MANAGEMENT, L.P. keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus